Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 17/20 | 0.76 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4206397 | 0.99 | HTR2A (0.74) | HTR2AOPRM1POLB | |
| SCHEMBL1646818 | 0.95 | HTR2A (0.68) | HTR2AOPRM1POLB | |
| SCHEMBL4911920 | 0.92 | HTR2A (0.62) | HTR2A | |
| SCHEMBL341912 | 0.91 | OPRM1 (0.67) | HTR2AOPRM1POLB | |
| SCHEMBL4916715 | 0.91 | HTR2A (0.63) | HTR2AOPRM1POLB | |
| Hydrochloric Acid SCHEMBL4212243 | 0.91 | HTR2A (0.61) | HTR2A | |
| SCHEMBL340689 | 0.90 | HTR2A (0.64) | HTR2AOPRM1 | |
| SCHEMBL1644855 | 0.90 | HTR2A (0.64) | HTR2AOPRM1 | |
| SCHEMBL4208529 | 0.90 | HTR2A (0.62) | HTR2AOPRM1 | |
| SCHEMBL340597 | 0.90 | HTR2A (0.62) | HTR2AOPRM1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4547250-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | Terran Biosciences Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| US-20250049748-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | TERRAN BIOSCIENCES INC (US) | 2025-02-13 | — | — | US | claimed |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-20 | — | — | US | claimed |
| US-20240165079-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | CONSEJO SUPERIOR INVESTIGACION (ES) | 2024-05-23 | — | — | US | claimed |
| EP-4313030-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | Terran Biosciences, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2024006984-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2024-01-04 | — | — | WO | claimed |
| US-20230330063-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | CONSEJO SUPERIOR INVESTIGACION (ES) | 2023-10-19 | — | — | US | claimed |
| US-11723894-B2 | Combination product for the treatment of neurological and/or psychiatric disorders | TERRAN BIOSCIENCES, INC. (US) | 2023-08-15 | — | — | US | claimed |
| WO-2023115002-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | TERRAN BIOSCIENCES INC. (US) | 2023-06-22 | — | — | WO | claimed |
| US-20230190714-A1 | PRIMARY METHODS AND PROCESSES FOR LIFE EXTENSION IN MODERN-DAY HUMANS | POSTREL RICHARD (US) | 2023-06-22 | — | — | US | claimed |
| EP-1263729-B1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | ACADIA PHARM INC (US) | 2006-12-20 | — | — | EP | claimed |
| US-20060194778-A1 | Serotonin receptor antagonist; psychological disorders; side effect reduction | ACADIA PHARMACEUTICALS, INC. | 2006-08-31 | — | — | US | claimed |
| US-20050014757-A1 | Azacyclic compounds | ANDERSSON CARL-MAGNUS A (DK) | 2005-01-20 | — | — | US | claimed |
| US-6815458-B2 | NERVOUS SYSTEM DISORDERS | ACADIA PHARMACEUTICALS, INC | 2004-11-09 | — | — | US | claimed |
| US-20030220316-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. | 2003-11-27 | — | — | US | claimed |
| JP-2003531829-A | — | — | 2003-10-28 | — | — | JP | claimed |
| CN-1443167-A | Azacyclo compounds for the treatment of 5-hydroxytryptamine related disorders | ACADIA PHARM INC (US) | 2003-09-17 | — | — | CN | claimed |
| EP-1263729-A1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | Acadia Pharmaceuticals Inc. (US) | 2002-12-11 | — | — | EP | claimed |
| US-20020004513-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. | 2002-01-10 | — | — | US | claimed |
| WO-2001066521-A1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | ACADIA PHARMACEUTICALS, INC. (US) | 2001-09-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330063-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | HTR2A, HTR2C, HTR1A | HTR2A 1/4885OPRM1 148/4885POLB 3427/4885 |
| US-20250049748-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | PNMT, HNMT, COMT | HTR2A 37/4885OPRM1 9/4885POLB 535/4885 |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR2A, HTR3A | HTR2A 2/4885OPRM1 34/4885POLB 3686/4885 |
| US-20030220316-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | HTR2A 10/4885OPRM1 210/4885POLB 1157/4885 |
| US-20020004513-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | HTR2A 10/4885OPRM1 210/4885POLB 1157/4885 |
| US-20240165079-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | HTR2A, HTR2C, HTR1A | HTR2A 1/4885OPRM1 173/4885POLB 3133/4885 |
| US-20050014757-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | HTR2A 10/4885OPRM1 210/4885POLB 1157/4885 |
| US-11723894-B2 | Combination product for the treatment of neurological and/or psychiatric disorders | HTR2A, HTR2C, HTR1A | HTR2A 1/4885OPRM1 173/4885POLB 3133/4885 |
| US-20060194778-A1 | Serotonin receptor antagonist; psychological disorders; side effect reduction | HTR2A, HTR1A, HTR1B | HTR2A 1/4885OPRM1 193/4885POLB 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.